Pharmaco‐EEG can be used to evaluate drug targets and for drug repurposing. For example, mecamylamine has recently been used as an Alzheimer's disease model (Simpraga et al., 2018). The described changes in behavior—as well as changes in EEG oscillations induced by mecamylamine—are highly reminiscent of AD, but are fully reversible. Although the effectiveness of drugs reversing the effects of such models is debatable, the systematic use of EEG during Phase II clinical trials could help in establishing a database that marks neuronal changes induced by drugs. This, in turn, could help in repurposing drugs for neurological and psychiatric disorders by investigating how changes in EEG patterns are resolved (Jobert et al., 2012).
